Exagen Inc. Common Stock
N/A
USD
N/A
N/A
...
Chart
Financials
Description
XGN Company Description
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
XGN Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view XGN Smart Score
Score Breakdown
XGN Company Description
Show More
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists. Show Less
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of XGN by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by XGN's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
Twitter
Followers on XGN's company Twitter account
WallStreetBets
Number of mentions of XGN in WallStreetBets Daily Discussion
XGN News
Recent insights relating to XGN
CNBC Recommendations
Recent picks made for XGN stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in XGN
Corporate Flights
Flights by private jets registered to XGN
Our Analysis